Celldex Therapeutics Management

Management Kriterienprüfungen 2/4

Celldex Therapeutics' CEO ist Anthony Marucci , ernannt in May 2003, hat eine Amtszeit von 21.08 Jahren. Die jährliche Gesamtvergütung beträgt $8.36M , bestehend aus 8.6% Gehalt und 91.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.043% der Aktien des Unternehmens, im Wert von $996.77K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 8 Jahre bzw. 11.4 Jahre.

Wichtige Informationen

Anthony Marucci

Geschäftsführender

US$8.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	8.6%
Amtszeit als Geschäftsführer	21.1yrs
Eigentum des Geschäftsführers	0.04%
Durchschnittliche Amtszeit des Managements	8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.4yrs

Jüngste Management Updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15

Celldex: Powerful Medicines To Yield Further Upsides

Jul 08

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

May 12

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Anthony Marucci im Vergleich zu den Einnahmen von Celldex Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$145m
Dec 31 2023	US$8m	US$721k	-US$141m
Sep 30 2023	n/a	n/a	-US$125m
Jun 30 2023	n/a	n/a	-US$113m
Mar 31 2023	n/a	n/a	-US$119m
Dec 31 2022	US$5m	US$693k	-US$112m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$100m
Mar 31 2022	n/a	n/a	-US$77m
Dec 31 2021	US$6m	US$669k	-US$71m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$66m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$3m	US$644k	-US$60m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$46m
Dec 31 2019	US$1m	US$619k	-US$51m
Sep 30 2019	n/a	n/a	-US$50m
Jun 30 2019	n/a	n/a	-US$46m
Mar 31 2019	n/a	n/a	-US$50m
Dec 31 2018	US$1m	US$608k	-US$151m
Sep 30 2018	n/a	n/a	-US$146m
Jun 30 2018	n/a	n/a	-US$165m
Mar 31 2018	n/a	n/a	-US$177m
Dec 31 2017	US$2m	US$598k	-US$93m

Vergütung im Vergleich zum Markt: AnthonyDie Gesamtvergütung ($USD8.36M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.66M).

Entschädigung vs. Einkommen: AnthonyDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Anthony Marucci (62 yo)

21.1yrs

Amtszeit

US$8,361,844

Vergütung

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anthony Marucci	Founder	21.1yrs	US$8.36m	0.043% $ 1.0m
Tibor Keler	Founder	21.1yrs	US$3.42m	0.011% $ 266.3k
Sam Martin	Senior VP	6.9yrs	US$2.95m	0.043% $ 1.0m
Margo Heath-Chiozzi	Senior Vice President of Regulatory Affairs	6.7yrs	US$2.94m	0.020% $ 484.5k
Diane Young	Senior VP & Chief Medical Officer	5yrs	US$2.97m	0.026% $ 619.8k
Joseph Schlessinger	Co-Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration	7yrs	keine Daten	0.0028% $ 67.3k
Freddy Jimenez	Senior VP & General Counsel	3.4yrs	US$2.17m	0.054% $ 1.3m
Ronald Pepin	Chief Business Officer & Senior VP	12.9yrs	US$1.23m	keine Daten
Elizabeth Crowley	Chief Product Development Officer & Senior VP	9.9yrs	US$1.18m	0.014% $ 328.6k
Richard Wright	Chief Commercial Officer & Senior VP	8.9yrs	US$563.17k	0.032% $ 754.4k

8.0yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von CLDX ist erfahren und erfahren (durchschnittliche Amtszeit: 7.9 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anthony Marucci	Founder	15.5yrs	US$8.36m	0.043% $ 1.0m
Joseph Schlessinger	Co-Founder & Member of Scientific Advisory Board	2.8yrs	keine Daten	keine Daten
Harry Penner	Independent Director	27.4yrs	US$371.19k	0.0042% $ 101.0k
Herbert Conrad	Independent Director	16.3yrs	US$364.94k	0.0039% $ 92.8k
Louis Weiner	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
James Marino	Independent Director	7.3yrs	US$377.44k	0.019% $ 459.9k
Karen Shoos	Independent Chair of the Board of Directors	23.1yrs	US$385.77k	0.0042% $ 101.0k
Carl June	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Michel Nussenzweig	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Marc Rothenberg	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Keith Brownlie	Independent Director	7yrs	US$373.27k	0.0010% $ 24.1k
Cheryl Cohen	Independent Director	2yrs	US$367.02k	0% $ 0

11.4yrs

Durchschnittliche Betriebszugehörigkeit

72yo

Durchschnittliches Alter

Erfahrener Vorstand: CLDXDie Vorstandsmitglieder sind sehr erfahren ( 11.4 ).

Celldex Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Recent updates

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 9.7% to US$69.43

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Consensus revenue estimates increase by 37%, EPS downgraded

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Price target increased by 7.4% to US$64.00

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

Price target decreased by 7.4% to US$59.57

Consensus revenue estimates decrease by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Now 20% undervalued after recent price drop

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

Consensus revenue estimates increase by 68%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Now 23% undervalued

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Founder exercised options and sold US$576k worth of stock

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Senior VP notifies of intention to sell stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces Board Appointments

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates fall by 25%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Senior VP exercised options and sold US$254k worth of stock

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Senior VP & Chief Medical Officer exercised options and sold US$150k worth of stock